CHARLES SCHWAB INVESTMENT MANAGEMENT INC - PHATHOM PHARMACEUTICALS INC ownership

PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 80 filers reported holding PHATHOM PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.6%.

Quarter-by-quarter ownership
CHARLES SCHWAB INVESTMENT MANAGEMENT INC ownership history of PHATHOM PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$2,558,082
-0.1%
246,681
+37.9%
0.00%0.0%
Q2 2023$2,561,418
+109.0%
178,870
+4.2%
0.00%
Q1 2023$1,225,274
-37.0%
171,607
-1.0%
0.00%
-100.0%
Q4 2022$1,943,910
+11.9%
173,254
+10.6%
0.00%0.0%
Q3 2022$1,737,000
+71.6%
156,680
+30.8%
0.00%
Q2 2022$1,012,000
-41.1%
119,814
-5.1%
0.00%
-100.0%
Q1 2022$1,718,000
-29.2%
126,187
+2.3%
0.00%0.0%
Q4 2021$2,426,000
-37.5%
123,299
+2.0%
0.00%0.0%
Q3 2021$3,880,000
+7.0%
120,871
+12.8%
0.00%0.0%
Q2 2021$3,627,000
+10.6%
107,120
+22.8%
0.00%0.0%
Q1 2021$3,278,000
+30.0%
87,256
+15.0%
0.00%0.0%
Q4 2020$2,522,000
-9.3%
75,898
+0.1%
0.00%0.0%
Q3 2020$2,780,000
+3.4%
75,787
-7.2%
0.00%0.0%
Q2 2020$2,688,000
+51.7%
81,668
+19.0%
0.00%0.0%
Q1 2020$1,772,000
-16.1%
68,603
+1.2%
0.00%0.0%
Q4 2019$2,111,00067,7870.00%
Other shareholders
PHATHOM PHARMACEUTICALS INC shareholders Q2 2021
NameSharesValueWeighting ↓
Medicxi Ventures Management (Jersey) Ltd 3,760,869$39,000,21212.45%
Frazier Life Sciences Management, L.P. 10,109,279$104,833,2236.96%
Decheng Capital Management III (Cayman), LLC 850,000$8,814,5002.94%
Carlyle Group Inc. 3,496,808$36,191,9631.57%
Ghost Tree Capital, LLC 395,000$4,096,1501.35%
Newtyn Management, LLC 500,000$5,185,0001.28%
Altium Capital Management LP 220,000$2,281,4001.19%
StepStone Group LP 422,085$4,377,0210.98%
MPM BioImpact LLC 347,332$3,601,8330.96%
NEA Management Company, LLC 1,276,595$12,238,2900.94%
View complete list of PHATHOM PHARMACEUTICALS INC shareholders